AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Scholar Rock Holding Corp (NASDAQ:SRRK)
35.45 USD
-0.360 1.005%Sponsored Reports
Loading...
| Previous Close (in USD) | 35.81 |
|---|---|
| Change | -0.360 1.005% |
| 52 W H/L (in USD) | 21.170/5.615 |
| EBITDA (in USD) | -186.496M |
| PE Ratio | -- |
| Volume | 370528 |
| Diluted Eps TTM | -2.02 |
| Total Assets (in USD) | 311.035M |
|---|---|
| Total Liabilities (in USD) | 85.817M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 101.855M |
| Market Cap (in USD) | 823.860 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -89.851M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Employees: 150
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Edward H. Myles M.B.A., MBA | CFO, COO & Treasurer | 1972 |
| 2. | Dr. Jay T. Backstrom M.D., M.P.H. | Pres, CEO & Director | 1955 |
| 3. | Ms. Catherine Hu | VP of Investor Relations & Corp. Communications | NA |
| 4. | Ms. Junlin Ho J.D. | Gen. Counsel & Corp. Sec. | 1979 |
| 5. | Ms. Caryn Parlavecchio | Chief HR Officer | 1972 |
| 6. | Ms. Lisa Amaya Price | Sr. VP of HR | NA |
| 7. | Dr. George G. Nomikos M.D., Ph.D. | Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area | NA |
| 8. | Ms. Erin Moore | Sr. VP of Fin. | 1975 |
| 9. | Mr. Ryan Iarrobino | Sr. VP of Clinical Devel. & Operations | NA |
| 10. | Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer | 1965 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.140 0.208% | 67.62 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.510 0.756% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-3.525 0.791% | 445.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.870 0.167% | 520 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -134.502M | -131.799M | -86.483M | -51M | -49.326M |
| Minority Interest | - | - | - | - | - |
| Net Income | -131.648M | -131.799M | -84.992M | -49.697M | -49.326M |
| Selling General Administrative | 43.119M | 40.269M | 28.219M | 20.817M | 14.382M |
| Gross Profit | 33.193M | 18.816M | 15.403M | 20.492M | -36.31M |
| Reconciled Depreciation | 2.986M | 2.627M | 1.491M | 1.303M | 0.807M |
| Ebit | -137.356M | -129.921M | -88.369M | -55.845M | -51.499M |
| Ebitda | -134.37M | -127.294M | -86.878M | -54.542M | -50.692M |
| Depreciation And Amortization | 2.986M | 2.627M | 1.491M | 1.303M | 0.807M |
| Operating Income | -134.37M | -129.921M | -86.878M | -54.542M | -50.692M |
| Other Operating Expenses | 167.563M | 148.737M | 102.281M | 75.034M | 50.692M |
| Interest Expense | -2.854M | 1.878M | 0M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | 1.422M |
| Net Interest Income | - | - | - | - | 1.422M |
| Income Tax Expense | -2.854M | 1.878M | -1.491M | -1.303M | 1.366M |
| Total Revenue | 33.193M | 18.816M | 15.403M | 20.492M | 0M |
| Total Operating Expenses | 167.563M | 148.737M | 102.281M | 75.034M | 50.692M |
| Cost Of Revenue | - | - | - | 54.217M | 36.31M |
| Total Other Income Expense Net | -0.132M | -1.878M | 0.395M | 3.542M | -0.056M |
| Net Income From Continuing Ops | -134.502M | -131.799M | -86.483M | -51M | -49.326M |
| Net Income Applicable To Common Shares | -134.502M | -131.799M | -86.483M | -51M | -49.326M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 311.035M | 358.168M | 304.445M | 388.305M | 196.381M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 7.18M | 12.663M | 12.325M | 3.373M | 27.719M |
| Total Liab | 85.817M | 97.933M | 132.371M | 127.535M | 83.48M |
| Total Stockholder Equity | 225.218M | 260.235M | 172.074M | 260.77M | 112.901M |
| Other Current Liab | 20.534M | 24.543M | 17.686M | 14.973M | 9.626M |
| Common Stock | 0.076M | 0.052M | 0.035M | 0.034M | 0.03M |
| Capital Stock | 0.076M | 0.052M | 0.035M | 0.034M | 0.03M |
| Retained Earnings | -676.421M | -510.632M | -376.13M | -244.331M | -157.848M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 4.217M | 343.571M | 3.519M | 2.596M |
| Cash | 101.855M | 103.275M | 212.835M | 160.358M | 36.308M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 32.741M | 36.389M | 64.297M | 42.564M | 32.814M |
| Current Deferred Revenue | - | - | 33.193M | 18.816M | 20.923M |
| Net Debt | -40.037M | -33.879M | -135.777M | -103.219M | -31.005M |
| Short Term Debt | 8.742M | 7.852M | 8.984M | 5.366M | 1.135M |
| Short Long Term Debt | 1.334M | - | 1.577M | - | - |
| Short Long Term Debt Total | 61.818M | 69.396M | 77.058M | 57.139M | 5.303M |
| Other Stockholder Equity | 901.471M | 771.699M | 548.204M | 505.069M | 270.682M |
| Property Plant Equipment | - | 7.384M | 9.564M | 8.121M | 8.618M |
| Total Current Assets | 288.194M | 328.024M | 265.319M | 344.404M | 185.167M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 178.083M | 212.086M | 40.159M | 180.673M | 121.14M |
| Net Receivables | 1.076M | - | - | 0M | 25M |
| Long Term Debt | 48.684M | 49.744M | 48.422M | 24.68M | 0.009M |
| Inventory | - | - | - | - | -25M |
| Accounts Payable | 3.465M | 3.994M | 4.434M | 3.409M | 1.13M |
| Accumulated Other Comprehensive Income | 0.092M | -0.884M | -0.035M | -0.002M | 0.037M |
| Non Currrent Assets Other | 4.417M | 4.217M | 4.12M | 3.519M | 2.596M |
| Non Current Assets Total | 22.841M | 30.144M | 39.126M | 43.901M | 11.214M |
| Capital Lease Obligations | 11.8M | 19.652M | 27.059M | 32.459M | 5.303M |
| Long Term Debt Total | - | 49.744M | 48.422M | 24.68M | 0.009M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -170.634M | 139.563M | -59.41M | -59.129M | -58.739M |
| Total Cashflows From Investing Activities | -171.698M | 134.315M | -63.498M | -62.236M | -60.231M |
| Total Cash From Financing Activities | 194.832M | 44.951M | 247.819M | 48.883M | 94.268M |
| Net Income | -134.502M | -131.799M | -86.483M | -51M | -49.326M |
| Change In Cash | -109.56M | 52.477M | 124.05M | -76.468M | 58.608M |
| Begin Period Cash Flow | 215.333M | 162.856M | 38.806M | 115.274M | 56.666M |
| End Period Cash Flow | 105.773M | 215.333M | 162.856M | 38.806M | 115.274M |
| Total Cash From Operating Activities | -132.694M | -126.789M | -60.271M | -63.115M | 24.571M |
| Depreciation | 2.986M | 2.627M | 1.491M | 1.303M | 0.807M |
| Other Cashflows From Investing Activities | - | - | - | 0.008M | -58.739M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | -0.456M | 0.669M | - |
| Sale Purchase Of Stock | 195.807M | 19.987M | 223.216M | 49.261M | 94.941M |
| Other Cashflows From Financing Activities | 0.492M | 31.856M | 31.897M | 0.9M | 0.006M |
| Capital Expenditures | 1.064M | 5.248M | 4.088M | 3.115M | 1.492M |
| Change In Working Capital | -34.389M | -28.44M | 11.242M | -21.165M | 67.896M |
| Other Non Cash Items | 5.51M | 6.732M | 2.438M | -0.401M | -0.289M |
| Free Cash Flow | -133.758M | -132.037M | -64.359M | -66.23M | 23.079M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price New Horizons | 1 year ago | 3944027 |
| 2. | US Small-Cap Growth II Equity Comp | 1 year ago | 3944027 |
| 3. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 3542756 |
| 4. | Polar Capital Biotech S Inc | 1 year ago | 2750000 |
| 5. | Fidelity Growth Company Fund | 1 year ago | 2725007 |
| 6. | SPDR® S&P Biotech ETF | 1 year ago | 2684428 |
| 7. | BB Biotech AG Ord | 1 year ago | 2132725 |
| 8. | Fidelity Select Biotechnology | 1 year ago | 1869699 |
| 9. | T. Rowe Price Health Sciences | 1 year ago | 1839021 |
| 10. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1765384 |
| 11. | iShares Russell 2000 ETF | 1 year ago | 1338891 |
| 12. | Biotech Growth Ord | 1 year ago | 1010532 |
| 13. | Fidelity Growth Company K6 | 1 year ago | 863832 |
| 14. | Fidelity Series Growth Company | 1 year ago | 746134 |
| 15. | T. Rowe Price New Horizons Tr-Z | 1 year ago | 738564 |
| 16. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 737728 |
| 17. | Fidelity Small Cap Index | 1 year ago | 565994 |
| 18. | iShares Russell 2000 Value ETF | 1 year ago | 532084 |
| 19. | Eventide Healthcare & Life Sciences I | 1 year ago | 525000 |
| 20. | Fidelity Advisor Biotechnology I | 1 year ago | 513280 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Artal Group S A | 1 year ago | 11259438 |
| 2. | FMR Inc | 1 year ago | 10414535 |
| 3. | T. Rowe Price Associates, Inc. | 1 year ago | 8208113 |
| 4. | Samsara BioCapital, LLC | 1 year ago | 6788609 |
| 5. | Redmile Group, LLC | 1 year ago | 6419610 |
| 6. | BlackRock Inc | 1 year ago | 4962597 |
| 7. | Orbimed Advisors, LLC | 1 year ago | 3574632 |
| 8. | Vanguard Group Inc | 1 year ago | 2969534 |
| 9. | Polar Capital Holdings PLC | 1 year ago | 2940672 |
| 10. | Goldman Sachs Group Inc | 1 year ago | 2861528 |
| 11. | Bellevue Group AG | 1 year ago | 2165203 |
| 12. | State Street Corporation | 1 year ago | 2159337 |
| 13. | Eventide Asset Management, LLC | 1 year ago | 1513280 |
| 14. | Geode Capital Management, LLC | 1 year ago | 1141547 |
| 15. | Woodline Partners LP | 1 year ago | 1061750 |
| 16. | Hood River Capital Management LLC | 1 year ago | 792047 |
| 17. | Deep Track Capital, LP | 1 year ago | 680000 |
| 18. | Morgan Stanley - Brokerage Accounts | 1 year ago | 584163 |
| 19. | Balyasny Asset Management LLC | 1 year ago | 562219 |
| 20. | Citigroup Inc | 1 year ago | 536329 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...